Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins

Molecular Carcinogenesis

Volumn 56, Issue 1, 2017, Pages 208-217

  Guaita Esteruelas, Sandra ^a,b,c   Bosquet, Alba ^a,b   Saavedra, Paula ^b   Gumà, Josep ^c   Girona, Josefa ^b   Lam, Eric W F ^d   Amillano, Kepa ^c   Borràs, Joan ^c   Masana, Lluís ^b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cancer progression; cell biology; lipid chaperones; lipid metabolism; metabolic pathways

Indexed keywords

FATTY ACID BINDING PROTEIN 4; FATTY ACID TRANSPORTER; FORKHEAD BOX PROTEIN M1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST; BREAST TUMOR; CELL MOTION; DISEASE COURSE; FEMALE; MAPK SIGNALING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FATTY ACID TRANSPORT PROTEINS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84963877426     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22485     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9–29.
2. Nimptsch K, Pischon T. Body fatness, related biomarkers and cancer risk: An epidemiological perspective. Horm Mol Biol Clin Investig 2015; 22:39–51.
3. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: Role in cancer promotion. Horm Mol Biol Clin Investig 2015; 21:57–74.
4. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise. Obes Rev 2015; 16:473–487.
5. Parkin DM BL. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer 2011; 6:S34–S37.
6. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance, and cancer. Proc Nutr Soc 2012; 71:181–189.
7. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci C 2002; 59:1096–1116.
8. Vogel Hertzel A, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: Molecular and genetic insights into function. Trends Endocrinol Metab 2000; 11:175–180.
9. Cabré A, Babio N, Lázaro I, et al. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. Atherosclerosis 2012; 222:229–234.
10. Cabré A, Lázaro I, Girona J, et al. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic Patients without microalbuminuri. Clin Chem 2008; 54:181–187.
11. Cabré A, Lázaro I, Girona J, et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008; 49b:1746–1751.
12. Cabré A, Lázaro I, Girona J, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007; 195:e150–e158.
13. Aragonès G, Ferré R, Lázaro I, et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010; 213:329–331.
14. Coll B, Cabre A, Alonso-Villaverde C, et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008; 199:147–153.
15. Lázaro I, Díaz M, Cabré A, Masana L, Ibáñez L. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecol Endocrinol 2011; 27:935–939.
16. Lázaro I, Ferré R, Plana N, et al. Lifestyle changes lower FABP4 plasma concentration in patients with cardiovascular risk. Rev Espaáola Cardiol 2012; 65:152–157.
17. Xu A, Wang Y, Xu JY, et al. Adipocyte Fatty Acid? Binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52:405–413.
18. Girona J, Rosales R, Plana N, Saavedra P, Masana L, Vallvé J-C. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS ONE 2013; 8:e81914.
19. Nieman KM, Penicka CV, Ladanyi A, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 30:1498–1503.
20. Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23:3865–3873.
21. Cataltepe O, Arikan MC, Ghelfi E, et al. Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol Appl Neurobiol 2012; 38:400–410.
22. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009; 124:1820–1828.
23. Tucker SL, Herbrich SM, Unruh AK, et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 2014; 20:3280–3288.
24. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010; 119:367–377.
25. Herroon M, Rajagurubandara E, Hardaway AL, et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 2013; 4:2108–2123.
26. Uehara H, Takahashi T, Oha M, Ogawa H, Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer 2014; 135:2558–2568.
27. Saavedra P, Girona J, Bosquet A, et al. New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. Biochim Biophys Acta 1853; 2015:2966–2974.
28. Koo C-Y, Muir KW, Lam EWF. FOXMI: From cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819:28–37.
29. Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: Is there a role of fatty acid metabolism? Biomed Res Int 2015; 2015:274585.
30. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: Local and systemic mechanisms. Annu Rev Med 2015; 66:297–309.
31. Mauro L, Naimo GD, Ricchio E, Panno ML, Andò S. Cross-talk between adiponectin and IGF-IR in breast cancer. Front Oncol 2015; 5:157.
32. Surmacz E. Leptin and adiponectin: Emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia 2013; 18:321–332.
33. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831; 2013:1533–1541.
34. Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs-mechanisms and therapeutic implications. Nat Rev Endocrinol 2015; 11:592–605.
35. Blanquer-Rosselló MDM, Oliver J, Sastre-Serra J, Valle A, Roca P. Leptin regulates energy metabolism in MCF-7 breast cancer cells. Int J Biochem Cell Biol 2016; 72:18–26.
36. Ravacci GR, Brentani MM, Tortelli TC, et al. Docosahexaenoic acid modulates a HER2-associated Lipogenic Phenotype, induces apoptosis, and increases trastuzumab action in HER2-overexpressing breast carcinoma cells. Biomed Res Ints 2015; 2015:838652.
37. Zhang F, Chen Y, Long J, Dong L, Wang Y, Chen Y. Dietary fatty acids affect lipid metabolism and estrogen receptor expression in N-methyl-N-nitrosourea-induced rat mammary cancer model. Clin Lab 2015; 61:389–395.
38. Nieva C, Marro M, Santana-Codina N, Rao S, Petrov D, Sierra A. The lipid phenotype of breast cancer cells characterized by Raman microspectroscopy: Towards a stratification of malignancy. PLoS ONE 2012; 7:e46456.
39. Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE 2015; 10:e0119473.
40. Merdad A, Karim S, Schulten H-J, et al. Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of adiponectin and fatty acid binding protein4: Is lipid metabolism associated with breast cancer? BMC Genomics 2015; 16:S11–S11.
41. Cao H, Sekiya M, Erikci M, et al. Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17:768–778.
42. Ertunc ME, Sikkeland J, Fenaroli F, et al. Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res 2015; 56:423–434.
43. Schlottmann I, Ehrhart-Bornstein M, Wabitsch M, Bornstein SR, Lamounier-Zepter V. Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int J Obes 2014; 38:1221–1227.
44. Wu LE, Samocha-Bonet D, Whitworth PT, et al. Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity. Mol Metab 2014;465–473.